劲方医药（上海）有限公司（以下简称“劲方医药-B”）研发的创新药物Gfh375，近日正式获得中国国家药品监督管理局（NMPA）授予的突破性治疗药物认定。
突破性治疗药物认定旨在加速具有突出临床价值的创新药研发与审评进程。Gfh375此次获得认定，标志着其在相关疾病治疗领域展现出显著的临床潜力。
该认定将有助于劲方医药-B加快推进Gfh375的后续临床开发、申报与上市进程，为患者提供新的治疗选择。
劲方医药（上海）有限公司（以下简称“劲方医药-B”）研发的创新药物Gfh375，近日正式获得中国国家药品监督管理局（NMPA）授予的突破性治疗药物认定。
突破性治疗药物认定旨在加速具有突出临床价值的创新药研发与审评进程。Gfh375此次获得认定，标志着其在相关疾病治疗领域展现出显著的临床潜力。
该认定将有助于劲方医药-B加快推进Gfh375的后续临床开发、申报与上市进程，为患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.